secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001628280-25-048814
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept Q3 revenue rises to $207.6M but net income drops; 2025 guidance modified to $800-850M
--------------------------------------------------------------------------------

- Revenue $207.6M (+14% YoY); net income $19.7M ($0.16 diluted EPS) vs $47.2M ($0.41) in Q3 2024.
- Modified 2025 revenue guidance to $800-850M, citing capacity constraints at prior specialty pharmacy.
- Cash and investments $524.2M; repurchased $50.6M in stock during Q3.
- NDA for relacorilant in hypercortisolism PDUFA Dec 30, 2025; NDA for ovarian cancer PDUFA July 11, 2026.
- New oncology trials starting: Phase 2 in earlier-stage ovarian, endometrial, cervical, pancreatic cancers; Phase 1b for nenocorilant with immunotherapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000162828025048814/0001628280-25-048814-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000162828025048814/cort-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-048814

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer